LISINOPRIL tablet

Country: Bandaríkin

Tungumál: enska

Heimild: NLM (National Library of Medicine)

Virkt innihaldsefni:

LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)

Fáanlegur frá:

Bryant Ranch Prepack

Stjórnsýsluleið:

ORAL

Gerð lyfseðils:

PRESCRIPTION DRUG

Ábendingar:

Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a va

Vörulýsing:

NDC: 71335-1295-1: 90 Tablets in a BOTTLE NDC: 71335-1295-2: 30 Tablets in a BOTTLE

Leyfisstaða:

Abbreviated New Drug Application

Vara einkenni

LISINOPRIL- LISINOPRIL TABLET
BRYANT RANCH PREPACK
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LISINOPRIL TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
LISINOPRIL TABLETS
LISINOPRIL TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1988
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•
•
INDICATIONS AND USAGE
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor
indicated for:
•
•
•
DOSAGE AND ADMINISTRATION
•
•
•
•
•
DOSAGE FORMS AND STRENGTHS
Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg (3)
CONTRAINDICATIONS
•
•
•
WARNINGS AND PRECAUTIONS
•
•
•
•
•
ADVERSE REACTIONS
Common adverse reactions (events 2% greater than placebo) by use:
•
WHEN PREGNANCY IS DETECTED, DISCONTINUE LISINOPRIL AS SOON AS
POSSIBLE. (5.1)
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH
TO THE DEVELOPING FETUS. (5.1)
Treatment of hypertension in adults and pediatric patients 6 years of
age and older (1.1)
Adjunct therapy for heart failure (1.2)
Treatment of Acute Myocardial Infarction (1.3)
Hypertension: Initial adult dose is 10 mg once daily. Titrate up to 40
mg daily based on blood pressure
response. Initiate patients on diuretics at 5 mg once daily (2.1)
Pediatric patients with glomerular filtration rate > 30 mL/min/1.73 m
: Initial dose in patients 6 years
of age and older is 0.07 mg per kg (up to 5 mg total) once daily (2.1)
2
Heart Failure: Initiate with 5 mg once daily. Increase dose as
tolerated to 40 mg daily (2.2)
Acute Myocardial Infarction (MI): Give 5 mg within 24 hours of MI.
Followed by 5 mg after 24 hours,
then 10 mg once daily (2.3)
Renal Impairment: For patients with creatinine clearance ≥ 10 mL/min
and ≤ 30 mL/min, halve usual
initial dose. For patients with creatinine clearance < 10 mL/min or on
hemodialysis, the
recommended initial dose is 2.5 mg (2.4)
Angioedema or a history of hereditary or idiopathic an